Breakthrough, cost-effective solutions for diseases affecting heart valves
Rheumatic Heart Disease (RHD) is a potentially deadly but preventable disease affecting at least 40 million people around the world – mostly in developing countries. Once patients become symptomatic, open-heart surgery is currently the only treatment. In developing countries, this is usually not feasible from a medical infrastructure, medical skills or cost perspective.
Strait Access Technologies’ (SAT) innovative RHD medical solutions eliminate this requirement for open-heart surgery. SAT’s heart valves are suited for younger RHD patients in whom conventional heart valve prostheses often degenerate rapidly.
SAT technology offers cost-effective and minimally-invasive transcatheter heart therapies, allowing RHD patients to undergo life-saving treatment where there is currently no alternative option.
SAT is redefining the treatment of heart valve diseases. As a world-first, we create durable transcatheter aortic valves specifically developed for Rheumatic Heart Disease (RHD), but also suited to Degenerative Heart Disease (DHD).